MedTrace Logo

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT06198413 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-07-01

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

GENETIC

LX102 subretinal injection

LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

Sponsors & Collaborators

  • Innostellar Biotherapeutics Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-12-26
Completion
2029-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06198413 on ClinicalTrials.gov